Boehringer: what’s in and what’s out?
A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.
GSK’s $625m TIGIT bet approaches crunch time
Readout of the delayed Galaxies Lung-201 study is due imminently.
Astra starts a pivotal lung cancer combo
Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.
FibroGen hopes to buck its pamrevlumab trend
Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.
AACR 2024 – Medicenna looks for a cytokine renaissance
After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.
AACR 2024 – a first look at Astra’s ATM inhibitor
One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.
